» Articles » PMID: 32029389

The Relationships Between Cancer and Autoimmune Rheumatic Diseases

Overview
Publisher Elsevier
Specialty Rheumatology
Date 2020 Feb 8
PMID 32029389
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Links between autoimmune rheumatic diseases and cancer continue to be elucidated. In this review, we explore this complex, bidirectional relationship. First, the increased risk of cancer across the breadth of the autoimmune rheumatic diseases is described. The magnitude of risk and types of tumors seen can differ by the type of autoimmune disease, timing of disease course, and even clinical and laboratory features within a particular autoimmune disease, suggesting that targeted cancer screening strategies can be considered. Multiple mechanisms linking autoimmune rheumatic diseases and cancer are discussed, including the development of autoimmunity in the context of naturally occurring anti-tumor immune responses and malignancy arising in the context of inflammation and damage from autoimmunity. Immunosuppression for rheumatic disease can increase risk for certain types of cancers. Finally, immune checkpoint inhibitors, a type of cancer immunotherapy, which cause a variety of inflammatory syndromes of importance to rheumatologists, are reviewed.

Citing Articles

Insights into autoimmunity and cancer.

Li X, Ufret-Vincenty C, Robinson-Hamm J, Kuo L, Park H, Shanmugam V Nat Immunol. 2025; 26(3):342-344.

PMID: 39920360 DOI: 10.1038/s41590-025-02078-x.


Spondyloarthritis and Risk of Malignancy: A Narrative Review on a Still Controversial Issue.

Favalli E, Grossi F, Batticciotto A, Filippini M, Parisi S, Viapiana O Rheumatol Ther. 2024; 12(1):25-36.

PMID: 39718763 PMC: 11751270. DOI: 10.1007/s40744-024-00734-6.


Dual Diagnosis: Unraveling Ankylosing Spondylitis in a Cancer Patient.

Galimova L, Safin R Cureus. 2024; 16(10):e72248.

PMID: 39583350 PMC: 11584544. DOI: 10.7759/cureus.72248.


Immune-Mediated Inflammatory Diseases and Cancer - a dangerous liaison.

Maier J, Castiglioni S, Petrelli A, Cannatelli R, Ferretti F, Pellegrino G Front Immunol. 2024; 15:1436581.

PMID: 39359726 PMC: 11445042. DOI: 10.3389/fimmu.2024.1436581.


Survival after surgery for lung cancer among patients with autoimmune diseases.

Nagano M, Cong Y, Nakao K, Kawashima M, Konoeda C, Sato M Surg Today. 2024; .

PMID: 39320491 DOI: 10.1007/s00595-024-02917-8.


References
1.
Smith M, Bass A . Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response. Arthritis Care Res (Hoboken). 2017; 71(3):362-366. DOI: 10.1002/acr.23467. View

2.
Judd J, Zibelman M, Handorf E, ONeill J, Ramamurthy C, Bentota S . Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist. 2017; 22(10):1232-1237. PMC: 5634771. DOI: 10.1634/theoncologist.2017-0133. View

3.
Postow M, Sidlow R, Hellmann M . Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378(2):158-168. DOI: 10.1056/NEJMra1703481. View

4.
Le Guenno G, Mahr A, Pagnoux C, Dhote R, Guillevin L . Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum. 2011; 63(5):1435-45. DOI: 10.1002/art.30296. View

5.
Joseph C, Darrah E, Shah A, Skora A, Casciola-Rosen L, Wigley F . Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2013; 343(6167):152-7. PMC: 4038033. DOI: 10.1126/science.1246886. View